KRAS and lung adenocarcinoma: Additional genes were identified using RNA-seq data from KRASG12C-mutant lung adenocarcinoma cell lines (H358 and H23) treated with a KRAS inhibitor and immortalized type II pneumocytes expressing an ER-KRASG12V fusion protein, which can be readily activated by administration of 4-hydroxytamoxifen (15).